drugset / Trial / NCT00293436
Celecoxib and Erlotinib in Treating Patients With Liver Cancer
Phase 1/2
Withdrawn
University of California, San Francisco
National Cancer Institute (NCI) · collab
Open-labelTreatment
Summary
RATIONALE: Celecoxib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Celecoxib may also stop the growth of liver cancer by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of giving celecoxib together with erlotinib and to see how well they work in treating patients with liver cancer.
Timeline
- Start
- 2005-01
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Celecoxib | Other / unclassified | — | Oral |
| Subject | Erlotinib | Small molecule | — | Oral |